Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aticaprant adjunctive therapy for major depressive disorder with anhedonia
2022-000439-22Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Aticaprant adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Change from baseline to Day 43 in Montgomery-Asberg Depression Rating Scale total score. Started Sep 2022; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2022-000439-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000439-22.